Anixa Biosciences (NASDAQ:ANIX) CEO Amit Kumar Buys 3,000 Shares

Anixa Biosciences Inc (NASDAQ:ANIX) CEO Amit Kumar purchased 3,000 shares of Anixa Biosciences stock in a transaction that occurred on Friday, July 24th. The stock was bought at an average cost of $3.73 per share, for a total transaction of $11,190.00. Following the purchase, the chief executive officer directly owned 643,812 shares in the company, valued at $2,401,418.76. This trade represents a 0.47% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Amit Kumar also recently made the following trade(s):

• On Monday, July 20th, Amit Kumar acquired 5,000 shares of Anixa Biosciences stock. The stock was bought at an average cost of $3.46 per share, with a total value of $17,300.00.
• On Monday, July 27th, Amit Kumar bought 3,188 shares of Anixa Biosciences stock. The stock was bought at an average price of $3.37 per share, for a total transaction of $10,743.56.
• On Monday, July 27th, Amit Kumar bought 5,000 shares of Anixa Biosciences stock. The stock was bought at an average price of $3.44 per share, for a total transaction of $17,200.00.
• On Friday, July 10th, Amit Kumar bought 5,000 shares of Anixa Biosciences stock. The shares were bought at an average cost of $3.04 per share, for a total transaction of $15,200.00.
• On Friday, June 12th, Amit Kumar purchased 21,000 shares of Anixa Biosciences stock. The shares were bought at an average cost of $2.50 per share, with a total value of $52,500.00.

Anixa Biosciences Stock Performance

Shares of NASDAQ ANIX opened at $3.52 on Wednesday. The firm has a market capitalization of $119.75 million, a price-to-earnings ratio of -11.35 and a beta of 0.59. The stock has a 50 day moving average price of $2.93 and a 200 day moving average price of $2.92. Anixa Biosciences Inc has a 52-week low of $2.32 and a 52-week high of $5.46.

Anixa Biosciences (NASDAQ:ANIX) last announced its quarterly earnings data on Wednesday, June 10th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.03. Analysts forecast that Anixa Biosciences Inc will post -0.31 earnings per share for the current year.

Hedge Funds Weigh In On Anixa Biosciences

Institutional investors and hedge funds have recently bought and sold shares of the company. NewEdge Advisors LLC purchased a new stake in shares of Anixa Biosciences during the 2nd quarter valued at $33,000. Cetera Investment Advisers acquired a new stake in shares of Anixa Biosciences in the 4th quarter worth $35,000. Northwestern Mutual Wealth Management Co. grew its stake in Anixa Biosciences by 2,000.0% during the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 10,500 shares of the company’s stock worth $35,000 after buying an additional 10,000 shares during the last quarter. Benjamin Edwards Inc. purchased a new position in Anixa Biosciences during the 2nd quarter worth $37,000. Finally, Millennium Management LLC acquired a new position in Anixa Biosciences during the 4th quarter valued at about $38,000. 29.13% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

ANIX has been the subject of a number of research reports. Wall Street Zen raised shares of Anixa Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday, June 20th. HC Wainwright reissued a “buy” rating on shares of Anixa Biosciences in a research report on Friday, June 12th. D. Boral Capital restated a “buy” rating and issued a $10.00 price target on shares of Anixa Biosciences in a report on Tuesday, June 30th. Zacks Research raised shares of Anixa Biosciences from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 21st. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Anixa Biosciences in a research note on Wednesday, June 17th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $8.50.

About Anixa Biosciences

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.